RHUMA-CURE
Composition
Each tablet contains:
Rofecoxib 12.5 or 25 mg[size=9]Properties and Mode of Action
RHUMA-CUREis a NSAID which inhibits prostaglandin synthesis by COX-2inhibition.So, it has analegesic and anti-inflmmatory actions with lowincidence of gastrointestinal side effects.Indications
Relief of signs and symptoms of osteoarthritis.
Relief of acute pain.
Treatment of Primary Dysmenorrhoea.Dosage and Administration
Osteoarthritis:
12.5 - 25 mg Once Daily.
Acute Pain and Primary Dysmenorrhoea:
50 mg Once Daily ( for not more than 5 days).Precautions
Cautionshould be used in patients with advanced renal dysfunction, moderate tosevere hepatic dysfunction, patients with hypertension, heart failureandpre-existing asthma or prior history of peptic ulcer or GI bleeding.Used in pregnancy and lactation only if the potential benefit justifiesthe potential risk.RHUMA-CURE use during the third trimester of pregnancy should beavoided.Drug Interactions
RHUMA-CURE can be used with low-dose aspirin and other anti-inflammatory drugs; however, care should be taken when combining RHUMA-CURE with those drugs, because gastric irritation may result.
NSAIDs may diminish the antihypertensive effect of ACE inhibitors andreduce the natriuretic effect of furosemide and thiazides . Thisinteraction should be given consideration in patients taking RHUMA-CURE concomitantly with ACE inhibitors and diuretics.
NSAIDs can elevate plasma Lithium levels and reduce its renal clearance; patients taking RHUMA-CURE and lithium concurrently should be observed for signs of lithium toxicity.
Rifampin 600 mg daily produced a 50% decrease in rofecoxib plasma concentration. A starting daily dose of 25 mg RHUMA-CURE should be considered for osteoarthritis treatment when co-administrated with rifampin.
RHUMA-CURE effects of recommended doses for osteoarthritis (12.5 and 25 mg) on plasma Methotrexate levels are unknown.Standard monitoring of Methotrexate toxicity should be observed when RHUMA-CURE and methotrexate are administered concomitantly.
Prothrombin time increased in healthy individuals receiving RHUMA-CURE and warfarin but this is unlikely to be clinically important in most patients.
Standard monitoring of PT values should be conducted when RHUMA-CURE is initiated or changed, particularly in the first few days, in patients receiving warfarin or similar agents. Contra_indications
Hypersensitivity to Rofecoxib.Patients who have experienced asthma, urticaria, or allergic-type reactionsafter taking aspirin or other NSAIDS.Side effects
RHUMA-CURE isgenerally well-tolerated.Indigestion, heartburn, nausea, diarrhoea, hypertension and lowerextremity oedema, dizziness, sinusitis, urinary tract infection,asthenia and fatigue may occur.Presentation
RHUMA-CURE 12.5 mg Tablets : Box of 1 blister of 10 tablets.
RHUMA-CURE 25 mg Tablets : Box of 1 blister of 10 tablets[/size]
Composition
Each tablet contains:
Rofecoxib 12.5 or 25 mg[size=9]Properties and Mode of Action
RHUMA-CUREis a NSAID which inhibits prostaglandin synthesis by COX-2inhibition.So, it has analegesic and anti-inflmmatory actions with lowincidence of gastrointestinal side effects.Indications
Relief of signs and symptoms of osteoarthritis.
Relief of acute pain.
Treatment of Primary Dysmenorrhoea.Dosage and Administration
Osteoarthritis:
12.5 - 25 mg Once Daily.
Acute Pain and Primary Dysmenorrhoea:
50 mg Once Daily ( for not more than 5 days).Precautions
Cautionshould be used in patients with advanced renal dysfunction, moderate tosevere hepatic dysfunction, patients with hypertension, heart failureandpre-existing asthma or prior history of peptic ulcer or GI bleeding.Used in pregnancy and lactation only if the potential benefit justifiesthe potential risk.RHUMA-CURE use during the third trimester of pregnancy should beavoided.Drug Interactions
RHUMA-CURE can be used with low-dose aspirin and other anti-inflammatory drugs; however, care should be taken when combining RHUMA-CURE with those drugs, because gastric irritation may result.
NSAIDs may diminish the antihypertensive effect of ACE inhibitors andreduce the natriuretic effect of furosemide and thiazides . Thisinteraction should be given consideration in patients taking RHUMA-CURE concomitantly with ACE inhibitors and diuretics.
NSAIDs can elevate plasma Lithium levels and reduce its renal clearance; patients taking RHUMA-CURE and lithium concurrently should be observed for signs of lithium toxicity.
Rifampin 600 mg daily produced a 50% decrease in rofecoxib plasma concentration. A starting daily dose of 25 mg RHUMA-CURE should be considered for osteoarthritis treatment when co-administrated with rifampin.
RHUMA-CURE effects of recommended doses for osteoarthritis (12.5 and 25 mg) on plasma Methotrexate levels are unknown.Standard monitoring of Methotrexate toxicity should be observed when RHUMA-CURE and methotrexate are administered concomitantly.
Prothrombin time increased in healthy individuals receiving RHUMA-CURE and warfarin but this is unlikely to be clinically important in most patients.
Standard monitoring of PT values should be conducted when RHUMA-CURE is initiated or changed, particularly in the first few days, in patients receiving warfarin or similar agents. Contra_indications
Hypersensitivity to Rofecoxib.Patients who have experienced asthma, urticaria, or allergic-type reactionsafter taking aspirin or other NSAIDS.Side effects
RHUMA-CURE isgenerally well-tolerated.Indigestion, heartburn, nausea, diarrhoea, hypertension and lowerextremity oedema, dizziness, sinusitis, urinary tract infection,asthenia and fatigue may occur.Presentation
RHUMA-CURE 12.5 mg Tablets : Box of 1 blister of 10 tablets.
RHUMA-CURE 25 mg Tablets : Box of 1 blister of 10 tablets[/size]